Article

SVR Achieved With 8-Week Course in Coinfected Hepatitis C Patients

Encouraging results with a shorter course of hepatitis C treatment were presented at the Digestive Disease Week meeting. Patients receiving an 8-week course of sofosbuvir and daclatasvir, previously naïve to direct-acting antiviral treatment, achieved a sustained response at 12 weeks.

Results, presented at the Digestive Disease Week meeting, from HIV-coinfected hepatitis C virus (HCV) patients receiving an 8-week course of sofosbuvir and daclatasvir, previously naïve to direct-acting antiviral treatment., were encouraging The data showed that once-daily daclatasvir combined with sofosbuvir, administered for 8 weeks, achieved a sustained virologic response in more than 75% of patients, 12 weeks after finishing the course.

While the treatment was well-tolerated overall, post-treatment hepatitis C virus relapse occurred in 1% to 2% of patients in the 12-week treatment groups and in about 25% in the 8-week group.

Read the complete article on MedPage Today: http://bit.ly/1c94yhg

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Dr Ibrahim Aldoss
Dr John Mascarenhas
5 experts are featured in this series
4 experts in this video
5 experts are featured in this series
4 experts in this video
1 expert is featured in this series.
Dr Pankit Vachhani
Screenshot of Ivo Abraham, PhD, RN, during a video interview
Dr John Mascarenhas
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo